October 29, 2021
Reston, VA—Long-term cognitive problems after a COVID-19 diagnosis may be a result of fatigue rather than pathological changes in the brain, according to a study published ahead-of-print in The Journal of Nuclear Medicine. An analysis of neuropsychological testing and 18F-FDG PET imaging showed that few or no objective impairments were observed in the cognition and brain pathology of long-COVID patients; however, many of the group suffered from subjective complaints such as severe fatigue.
The term “long-COVID syndrome” is used to describe symptoms that arise in the aftermath of a COVID-19 infection (usually defined as being present later than 12 weeks after the infection), including cognitive deficits—such as brain fog, memory loss and attention problems—as well as fatigue and exhaustion. The underlying cause of these symptoms is unknown.
Previously published studies showed that patients needing inpatient treatment because of newly diagnosed COVID-19 have reduced glucose metabolism in the brain, which is associated with impaired cognitive function. To assess whether patients suffering from long COVID experience similar deficits, researchers conducted neuropsychological testing and cerebral 18F-FDG PET imaging.
Thirty-one patients who sought counseling for persistent neurocognitive symptoms were included in the present study. Patients participated in a battery of neuropsychological tests, and the results were analyzed to determine cognitive impairment levels. Average group results of the testing showed no impairment. Mild deficits were observed in some patients on the single-subject level, however, mainly in regard to visual memory.
18F-FDG PET imaging was recommended to all patients who received counseling, and 14 of the 31 patients proceeded. Clinical assessment of each patient’s scan revealed no distinct pathological findings or alternative diagnoses. When the scans were compared to those of a control group, no significant differences were noted.
The lack of significant findings on 18F-FDG PET scans and only mild impairments on neuropsychological testing is in contrast to the severe and lasting disability self-reported by the patients. Fatigue, however, was particularly prevalent in the group, reported by 61 percent of study participants. Fatigue often follows viral infections and inflammation and has been related to immune processes and chronic fatigue syndrome in long COVID.
“This suggests that the fatigue, not brain regional dysfunction, may be responsible for many long-COVID symptoms,” the researchers concluded.
|Figure 2. 18F-FDG PET in patients with long-COVID syndrome. A and B: Transaxial sections of group averaged, spatially normalized 18F-FDG PET scans in patients with long-COVID syndrome (A) and control patients (B). C: The pattern expression score (PES; *adjusted for age and sex, for illustration purposes) of the previously established COVID-19-related spatial covariance pattern was not significantly different between patients with long-COVID syndrome and control patients. Boxplots (grey), as well as individual values for COVID-19 patients (red) and the control cohort (green), are displayed.|
The authors of “Neuropsychological profiles and cerebral glucose metabolism in neurocognitive long-COVID syndrome” include Andrea Dressing, Tobias Bormann and Cornelius Weiller, Department of Neurology and Clinical Neuroscience, Medical Center–University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, and Freiburg Brain Imaging Center, Medical Center–University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Ganna Blazhenets, Johannes Thurow, and Philipp T. Meyer, Department of Nuclear Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Nils Schroeter, Lea I. Walter and Jonas A. Hosp, Department of Neurology and Clinical Neuroscience, Medical Center–University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Dietrich August, Hanna Hilger, Katarina Stete, Siegbert Rieg and Dirk Wagner, Division of Infectious Diseases, Department of Medicine II, Medical Center–University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Kathrin Gerstacker and Susan Arndt, Department of Otorhinolaryngology ‐ Head and Neck Surgery, Medical Center–University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; and Alexander Rau and Horst Urbach, Department of Neuroradiology, Medical Center–University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or email@example.com.
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 11 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.